Pliant Therapeutics Inc
NASDAQ:PLRX 3:59:52 PM EDT
| Market Cap (Intraday) | 1.06B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $30.60 |
| 50-Day MA | $34.98 |
| 200-Day MA | $27.78 |
Pliant Therapeutics Inc Stock, NASDAQ:PLRX
260 Littlefield Avenue, South San Francisco, California 94080
United States of America
Phone: +1.650.481.6770
Number of Employees: 78
Description
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-Ã?Å?1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.